ROTUNNO, GIADA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.377
EU - Europa 2.897
AS - Asia 1.762
SA - Sud America 259
AF - Africa 33
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 1
Totale 9.346
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.349
RU - Federazione Russa 1.084
SG - Singapore 541
CN - Cina 488
PL - Polonia 477
IT - Italia 441
HK - Hong Kong 292
IE - Irlanda 219
BR - Brasile 212
SE - Svezia 173
KR - Corea 168
DE - Germania 119
FI - Finlandia 89
VN - Vietnam 88
GB - Regno Unito 76
CH - Svizzera 70
FR - Francia 60
IN - India 48
JO - Giordania 39
ID - Indonesia 24
NL - Olanda 24
ES - Italia 20
CA - Canada 18
AR - Argentina 17
AU - Australia 17
BD - Bangladesh 12
CI - Costa d'Avorio 12
EC - Ecuador 9
MX - Messico 9
AT - Austria 8
BE - Belgio 8
JP - Giappone 8
TW - Taiwan 7
UA - Ucraina 7
UZ - Uzbekistan 7
IQ - Iraq 6
PK - Pakistan 6
BG - Bulgaria 5
PY - Paraguay 5
SA - Arabia Saudita 5
TR - Turchia 5
ZA - Sudafrica 5
AE - Emirati Arabi Uniti 4
CO - Colombia 4
PE - Perù 4
VE - Venezuela 4
EG - Egitto 3
KE - Kenya 3
MA - Marocco 3
MY - Malesia 3
RO - Romania 3
AL - Albania 2
BJ - Benin 2
CL - Cile 2
IL - Israele 2
PH - Filippine 2
TN - Tunisia 2
AZ - Azerbaigian 1
BH - Bahrain 1
BO - Bolivia 1
BY - Bielorussia 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DZ - Algeria 1
EE - Estonia 1
EU - Europa 1
GR - Grecia 1
HU - Ungheria 1
IM - Isola di Man 1
IR - Iran 1
KH - Cambogia 1
KZ - Kazakistan 1
LT - Lituania 1
LV - Lettonia 1
NO - Norvegia 1
NP - Nepal 1
OM - Oman 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SV - El Salvador 1
UY - Uruguay 1
YT - Mayotte 1
Totale 9.346
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.073
Warsaw 470
Ashburn 465
Fairfield 414
Singapore 348
Hong Kong 252
Woodbridge 225
Chandler 222
Dublin 219
Seattle 201
Seoul 168
Cambridge 158
Houston 157
Wilmington 147
Beijing 135
Ann Arbor 112
Hefei 105
Florence 97
Altamura 82
Lawrence 80
Bern 70
Buffalo 69
Princeton 60
Los Angeles 59
Dallas 52
Munich 52
Boston 37
New York 35
Moscow 34
Turku 34
Bremen 30
Shanghai 30
London 29
San Diego 29
Clifton 26
Mumbai 26
Helsinki 25
Paris 25
São Paulo 25
Ho Chi Minh City 24
Kent 24
Medford 21
The Dalles 21
Melbourne 17
Redondo Beach 17
Hanoi 16
Barcelona 15
Jakarta 15
Boardman 14
Rome 13
Abidjan 12
Brooklyn 12
Dearborn 12
Dong Ket 12
Milan 12
Hillsboro 11
Norwalk 9
Brussels 8
Claymont 8
Fuzhou 8
Chicago 7
Hangzhou 7
Pune 7
Tashkent 7
Amsterdam 6
Cagliari 6
Chennai 6
Fiesole 6
Frankfurt am Main 6
Montreal 6
Phoenix 6
Pian di Scò 6
San Jose 6
Tokyo 6
Vienna 6
Campinas 5
Düsseldorf 5
Elk Grove Village 5
Manchester 5
Mexico City 5
Porto Alegre 5
Andover 4
Belo Horizonte 4
Biên Hòa 4
Blagoevgrad 4
Brasília 4
Cantagallo 4
Castel Maggiore 4
Charlotte 4
Curitiba 4
Guangzhou 4
Haiphong 4
Jacksonville 4
Jinan 4
Johannesburg 4
Lappeenranta 4
Nanjing 4
Red Deer 4
Redwood City 4
Rio de Janeiro 4
Totale 6.378
Salva come PNG Salva come JPEG
Nome #
Study of mutation complexity in Chronic Myeloproliferative Neoplasms: pathogenetic insights and translational relevance 345
Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis 310
Feasibility of a workflow for the molecular characterization of single cells by next generation sequencing 267
Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer 267
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis 228
Epidemiology and clinical relevance of mutations in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study on 359 patients of the AGIMM group 218
Spectrum of ASXL1 mutations in primary myelofibrosis: Prognostic impact of the ASXL1 p.G646Wfs∗12 mutation 208
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients 206
Targeted deep sequencing in polycythemia vera and essential thrombocythemia 195
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis 192
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: Pathogenetic insight and diagnostic value 186
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis 186
Germline transmission of LNKE208Q variant in a family with myeloproliferative neoplasms 186
Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs) 184
Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib 183
Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in Primary Myelofibrosis 183
Mutations and prognosis in primary myelofibrosis. 177
JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib 177
Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms. 176
Myelodysplasia as assessed by multiparameter flow cytometry refines prognostic stratification provided by genotypic risk in systemic mastocytosis 173
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. 172
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea 171
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients 169
Immunohistochemistry analysis of bone marrow biopsies in multiple sclerosis patients undergoing autologous haematopoietic stem cells transplantation 165
ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera 163
A systematic analysis of bone marrow cells by flow cytometry defines a specific phenotypic profile beyond GPI deficiency in paroxysmal nocturnal hemoglobinuria. 163
Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms. 163
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis 162
Mutational analysis of BCORL1 in the leukemic transformation of chronic myeloproliferative neoplasms. 160
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. 157
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. 156
Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis 152
Validation of the Mayo alliance prognostic system for mastocytosis 152
CALR mutation burden in essential thrombocythemia and disease outcome 149
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. 147
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. 145
RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features 143
Calreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasms. 142
Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis 137
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project 136
What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice? 135
Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera 133
Prognotic Impact of Mutations in Systemic Mastocytosis 130
The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis 128
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC project 128
A case of aleukemic mast cell leukemia with an underlying myeloproliferative neoplasm: Morphological and molecular characteristics of a highly aggressive disease 128
Concomitant myeloproliferative neoplasm with eosinophilia, B and T cell lymphoblastic lymphoma/leukemia and mast cell proliferation driven by ZMYM2::FGFR1 rearrangement 127
Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms 120
Lenalidomide: A double-edged sword for concomitant multiple myeloma and post-essential thrombocythemia myelofibrosis 114
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia 113
Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients 112
Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis 112
BRAFV600E mutation in the wrong place: a case of concomitant polycythemia vera, hairy cell leukemia, and thyroid adenoma 110
SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates 106
Impact of baseline genetic profile and treatment on outcome and hematological toxicity in CEBPA-mutated AML 105
Prognostic relevance of mutations in myelofi-brosis 101
Prognostic stratification in venetoclax-based acute myeloid leukemia treatments: the molecular prognostic risk signature tested in a real-world setting 93
Clonal dynamics and copy number variants by single-cell analysis in leukemic evolution of myeloproliferative neoplasms 90
null 47
Totale 9.483
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.987
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.987
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021351 0 0 0 0 0 49 31 40 67 76 54 34
2021/2022379 9 8 48 17 20 21 13 40 20 14 74 95
2022/20231.160 87 228 72 79 71 173 140 89 103 13 26 79
2023/2024481 25 40 64 18 51 60 12 102 11 32 34 32
2024/20253.139 84 283 196 502 845 494 72 144 130 101 141 147
2025/20261.863 423 408 302 322 384 24 0 0 0 0 0 0
Totale 9.483